公司資料
Petros Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- PTPI
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.00 USD (-51.47%)
收盤價
最後更新: 2026年10月1日
—
市值
股價為何變動
截至 2026年10月1日，PTPI 下跌 51.5%，收於 $0.0033。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Rx-to-OTC Technology Developer
Petros Pharmaceuticals is developing technology intended to help prescription medicines transition to nonprescription use. The company has exited its former commercial pharmaceutical and men's-health device businesses.
Software-as-a-Service Platform
The planned platform is intended to help pharmaceutical companies design and operate consumer-facing processes required for prescription-to-over-the-counter switches. Potential functions include education, self-selection, eligibility logic, and commercialization support.
Consumer Decision Interface
Petros is also developing a potential Software as a Medical Device component that would guide consumers through appropriate self-selection or deselection. The interface is intended to reduce subjectivity through clinically established decision logic.
ACNU Regulatory Framework
The strategy is aligned with the FDA's framework for nonprescription drug products with an additional condition for nonprescription use. Under this model, technology can help consumers use a medicine safely when the drug label alone is insufficient.
Discontinued Legacy Operations
Petros no longer commercializes STENDRA and has assigned the assets of its former vacuum-erection-device businesses to a third party. The company therefore operates as an early-stage technology developer rather than a current product marketer.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。